Page 48 - CPG - Clinical Practice Guidelines - Management of Cancer Pain
P. 48

Management of Cancer Pain (Second Edition)
                  Management  strategies include awareness  and recognition  of the
                  AEs,  symptomatic  management  of  individual AEs  and adjustment of
                  opioid dosages, including dose reduction and opioid switching. Refer
                  to $SSHQGL[  D for 6XJJHVWHG 0HGLFDWLRQ 'RVDJHV DQG $GYHUVH
                  (YHQWV LQ $GXOWV  The management of the side effects is discussed
                  below.
                  •  Constipation
                    {  Constipation is the commonest reported AE with a 25% incidence
                      rate. 53, level I
                    {  &RQFXUUHQW  SURSK\OD[LV  IRU  FRQVWLSDWLRQ  H J   VWLPXODQWV  DQG
                      VRIWHQLQJ  OD[DWLYHV  LV  UHFRPPHQGHG  IRU  DOO  SDWLHQWV  RQ  UHJXODU
                      opioid therapy. 9
                    {  The rate of constipation is lower for fentanyl than morphine. 54,
                      level I  Thus, fentanyl can be considered as an alternative in severe
                      morphine-induced constipation. 9
                  •  Nausea and vomiting
                    {  Nausea occurs in 21% while vomiting in 13% of patients on opioid
                      therapy. 53, level I
                    {  These AEs are temporary and tolerance commonly develops in 5
                      -10 days after initiation of opioids. 9
                    {  Anti-emetics e.g. metoclopramide, haloperidol and prochlorperazine
                      can be used to treat these AEs. 9
                  •  Dry mouth
                    {  The incidences of dry mouth are variable, ranging from 17% 53, level I
                      to 94%. 54, level I
                    {  It is particularly important, as patients on opioid therapy rated the
                      symptom as moderate to severe. 54, level I  Non-pharmacological
                      measures e.g. oral hygiene, sugar-free chewing gum/candies,
                      and saliva stimulant mouth spray/gel can be offered to patients to
                      improve their symptoms.
                  ‡  6HGDWLRQ DQG GURZVLQHVV
                    {  6HGDWLRQ FDQ RFFXU DW WKH LQLWLDWLRQ RI RSLRLG WKHUDS\ DQG WHQGV WR
                      resolve within a week. 9
                    {  6RPQROHQFH LV UHSRUWHG LQ     RI SDWLHQWV 53, level I  and drowsiness
                      LQ  XS  WR        ZLWK  WKH  UDWH  RI  GURZVLQHVV  KLJKHU  LQ  R[\FRGRQH
                      compared with other opioids, even where low doses are used. 54, level I
                    {  In many patients, symptoms are brief and patient education
                      LV  VXI¿FLHQW   )RU  SDWLHQWV  ZLWK  FR PRUELGLWLHV   PHWDEROLF
                      encephalopathy, dementia) and on concomitant sedation use,
                                              9
                      prolonged sedation may occur.
                    {  Management strategies include dose reduction, titration using the
                                                         9
                      lowest effective dose, and opioid switching.  Methylphenidate and
                      other psychostimulant drugs can be considered if necessary. 9; 40
                  ‡  'HOLULXP DQG QHXURWR[LFLW\  LQFOXGLQJ FRQIXVLRQ DQG P\RFORQXV
                    {  Transient mild cognitive impairment may occur upon opioid initiation
                      and usually resolves within 1 - 2 weeks. 9


                                             30




          e-cpg inside text-Cancer pain-25/5/24.indd   30               09/08/2024   12:09 AM
   43   44   45   46   47   48   49   50   51   52   53